DRTS - Alpha Tau Medical Ltd logo

Alpha Tau Medical Ltd

DRTS

Alpha Tau Medical Ltd develops and commercializes diffusing alpha-emitters radiation therapy (Alpha DaRT) for treating solid tumors, including skin, pancreatic, prostate, lung, liver, and breast cancers, currently in clinical trials.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$1,327today

Score Overview

1 Year
Scoreโ€”
Net Growth-117.17%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-239.46%
Net Trend20%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-239.46%
Net Trend20%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Alpha Tau Medical Ltd has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. DRTS does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 13.16โ€”
1 Year2025-10-23
$ 4.21212.59%
5 Years2021-10-22
$ 9.9232.66%
All Time2021-03-08
$ 10.1030.30%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 92M$ 100M
2025$ 0.00-$ 42M$ 76M
2024$ 0.00-$ 31M$ 59M
2023$ 0.00-$ 29M$ 81M
2022$ 0.00-$ 33M$ 104M
IPO2021$ 0.00-$ 27M$ 31M
DRTS - Alpha Tau Medical Ltd logo

Alpha Tau Medical Ltd fundamental performance

Across Alpha Tau Medical Ltd's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 27M to -$ 42M. Revenue increased in 0% of the years measured; net income in 20%.

Membership

Explore DRTS with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies